Gastrointestinal cancers still claim a disproportionate share of global cancer burden—about one fifth of all cases and roughly one third of cancer deaths worldwide. Yet, compared with many other tumor types, systemic treatment options remain limited. In this context, antibody–drug conjugates (ADCs)—precision medicines that marry an antibody to a potent cytotoxic payload through a chemical linker—have quickly gained momentum over the past decade. Their expanding success in solid tumors and hematologic malignancies has made them a high-profile platform for addressing otherwise refractory cancers.
Despite that promise, GI cancers have lagged behind. The pace of ADC development has been slower, with fewer targetable pathways and more complex clinical realities. A key question has been whether newer ADC designs can deliver reliably in GI tumor biology and the unique microenvironment encountered in stomach, colorectal, pancreatic, and related cancers.
Recent clinical signals suggest that the answer is starting to change. Investigators have reported encouraging activity for ADCs aimed at Claudin 18.2, CEACAM5, and MET—three targets with distinct expression patterns and potential relevance across multiple GI cancer settings. The emerging data point to a broader theme: selecting the right target is necessary, but not sufficient for consistent therapeutic effect.
A major evolution in ADC technology is the shift in payload class. Earlier-generation ADCs frequently used tubulin inhibitors, but newer designs increasingly favor topoisomerase I inhibitors. This transition appears to enhance overall antitumor activity in GI cancers, particularly in adenocarcinoma, where improved cytotoxic potency and downstream DNA damage may better match tumor vulnerabilities.
The apparent benefit is especially notable for MET- and CEACAM5-directed ADCs. These targets have now become test cases for a payload strategy that seems to translate into stronger clinical performance. Importantly, the pattern does not appear limited to these antigens.
The same “payload switch” trend may also extend to ADCs targeting other widely prevalent GI markers. That raises the prospect of more generalizable design rules: optimize target biology, choose an effective cytotoxic mechanism, and ensure that linker behavior supports efficient payload delivery to cancer cells.
Still, the field faces development hurdles. Differences in antigen density, heterogeneous target expression, and variable internalization can constrain the amount of drug delivered. In addition, GI tumors may present distinctive resistance mechanisms, complicating the interpretation of modest versus meaningful clinical responses.
Researchers are therefore looking toward emerging solutions—ranging from refined linker chemistry and improved conjugation strategies to better patient selection based on biomarker performance and tumor distribution. Together, these approaches aim to convert promising signals into durable, broadly applicable therapies.
If the momentum continues, ADCs could reshape GI oncology by expanding both the number of usable targets and the likelihood of therapeutic success. The review by Cassier and colleagues frames this as the next competitive frontier: not just building ADCs, but engineering them to overcome the particular constraints of gastrointestinal disease.
Subject of Research: Antibody–drug conjugates (ADCs) in gastrointestinal cancers
Article Title: Advancing antibody drug conjugates in gastrointestinal cancers
Article References: Cassier, P.A., Izarn, F., Dumontet, C. et al. Advancing antibody drug conjugates in gastrointestinal cancers. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03510-1
Image Credits: AI Generated
DOI: 10.1038/s41416-026-03510-1
Keywords:
